Gender Specificity of the Effect of Neonatal Melatonin Administration on Lifespan and Age-Associated Pathology in 129/Sv Mice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Melatonin is subcutaneously administered in a single dose of 1.2 μg to 129/Sv mice at days 3, 5, and 7 after birth, and the mice are observed until natural death. In adult males, a decrease in the body weight and a reduction of the contribution of lung lesions detected during postmortal autopsy to mortality are detected. In adult females, an increase in the proportion of mice with impaired estrous cycle at the later stages of life and an acceleration of the mortality associated with uterine hemangioma are observed with the absence of any effect of melatonin on the body weight. Changes in the frequency of detection of other tumors are multidirectional: there is a decrease in the frequency in males and an increase in females. The age of death of the last 25% and 10% of males increases, while in females it decreases. An analysis of the complete survivorship curves using the Gompertz model does not reveal changes in the rate of aging and initial mortality sufficient to go beyond the limits determined by the artifact component of the Strehler–Mildvan correlation between these parameters. In general, the tendencies noted in males and females are multidirectional: favorable and unfavorable, respectively. Melatonin is contraindicated for pregnant and nursing women and children under 18 years old. The gender specificity of the effects of melatonin, apparently, should be considered when assessing the feasibility of its prescription to these categories.

About the authors

M. N. Yurova

Petrov National Medical Research Center of Oncology

Author for correspondence.
Email: aging@mail.ru
Russian Federation, St. Petersburg, 197758

M. L. Tyndyk

Petrov National Medical Research Center of Oncology

Email: aging@mail.ru
Russian Federation, St. Petersburg, 197758

I. G. Popovich

Petrov National Medical Research Center of Oncology

Email: aging@mail.ru
Russian Federation, St. Petersburg, 197758

A. G. Golubev

Petrov National Medical Research Center of Oncology

Email: aging@mail.ru
Russian Federation, St. Petersburg, 197758

V. N. Anisimov

Petrov National Medical Research Center of Oncology

Email: aging@mail.ru
Russian Federation, St. Petersburg, 197758


Copyright (c) 2019 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies